OTHER PUBLICATIONS & ABSTRACTS
Other Data
Evidence / Other
Identification of a Low-Risk Subgroup of HER-2-Positive Breast Cancer by the 70-gene Prognosis Signature
PUBLICATION: Br J Cancer. 2010 Dec 7; 103(12): 1788–1793. Published online 2010 Nov 16. doi: 10.1038/sj.bjc.6605916. AUTHORS: M. Knauer, F. Cardoso, J. Wesseling, P.L. Bedard, S.C. Linn, E.J.T. Rutgers, and L.J. van't Veer Background: Overexpression of HER-2 is observed in 15–25% of breast cancers, and is associated with increased risk Read More
Comparison of MammaPrint and TargetPrint Results with Clinical Parameters in German Patients with Early Stage Breast Cancer
PUBLICATION: Int J Mol Med. 2010 Dec;26(6):837-43. AUTHORS: Gevensleben H., Göhring U.J., Büttner R., Heukamp L.C., Kunz G., Dimpfl T., Jackisch C., Ortmann O., Albert U.S., Bender R., De Snoo F., Krijgsman O., Glas A.M., Ergönenc Y.H., Vogel C., Dykgers A., Langwieder C., Rees M., Anzeneder T. SUMMARY: Thirty-two percent Read More
Biological Functions of the Genes in the MammaPrint® Breast Cancer Profile Reflect the Hallmarks of Cancer
PUBLICATION: Biomarker Insights. 2010 Nov 28;5:129-38. doi: 10.4137/BMI.S6184. AUTHORS: Tian S., Roepman P., Van't Veer L.J., Bernards R., de Snoo F., Glas A.M. SUMMARY: The study included 3090 clinical low-risk patients with unifocal and 238 patients with multifoGenes in the MammaPrint gene signature comprehensively measure the six hallmarks of cancer-related Read More
MammaPrint® Translating Research into a Diagnostic Test
PUBLICATION: Molecular Diagnostics: The Key in Personalized Cancer Medicine 2010; pg. 26; Chapter 7 AUTHORS: Annuska M. Glas, Leonie Delahaye, Oscar Krijgsman SUMMARY: Book Chapter: This chapter describes all important critical steps being met for the implementation of a multi-marker microarray (MammaPrint®) as a routine diagnostic tool. Read more: MammaPrint Read More
Cost-effectiveness of the 70-gene Signature Versus St. Gallen Guidelines and Adjuvant Online for Early Breast Cancer
PUBLICATION: Eur J Cancer. 2010 May;46(8):1382-91. doi: 10.1016/j.ejca.2010.02.035. Epub 2010 Mar 30. AUTHORS: Retèl V.P., Joore M.A., Knauer M., Linn S.C., Hauptmann M., Harten W.H. SUMMARY: Pooled analysis: he 70-gene has the highest probability of being cost-effective for a willingness to pay for a QALY higher than euro12.000. Sankt Gallen Read More
Clinical Utility of the 70-gene MammaPrint Profile in a Japanese Population
PUBLICATION: Japanese Journal of Clinical Oncology, Volume 40, Issue 6, June 2010, Pages 508–512, https://doi.org/10.1093/jjco/hyp195. AUTHORS: Makoto Ishitobi, Teodora E. Goranova, Yoshifumi Komoike, Kazuyoshi Motomura, Hiroki Koyama, Annuska M. Glas, Ellen van Lienen, Hideo Inaji, Laura J. Van't Veer, Kikuya Kato SUMMARY: A small observational study in a Japanese Cohort Read More
Validation of 70-gene Prognosis Signature in Node-Negative Breast Cancer
PUBLICATION: Breast Cancer Res Treat. 2009 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2. Epub 2008 Sep 26. AUTHORS: Bueno-de-Mesquita J.M., Linn S.C., Keijzer R., Wesseling J., Nuyten D.S., van Krimpen C., Meijers C., de Graaf P.W., Bos M.M., Hart A.A., Rutgers E.J., Peterse J.L., Halfwerk H., de Groot R., Pronk A., Floore A.N., Glas Read More
